東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Lung cancer = new understandings and...

Chiang, Anne C.

FindBook

Google Book

Amazon

博客來

Lung cancer = new understandings and therapies /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Lung cancer/ edited by Anne C. Chiang, Roy S. Herbst.
其他題名:	new understandings and therapies /
其他作者:	Chiang, Anne C.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	vi, 264 p. :ill. (some col.), digital ;24 cm.
內容註:	Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
Contained By:	Springer Nature eBook
標題:	Lungs - Cancer -
電子資源:	https://doi.org/10.1007/978-3-030-74028-3
ISBN:	9783030740283

Lung cancer = new understandings and therapies /
Lung cancernew understandings and therapies /[electronic resource] :edited by Anne C. Chiang, Roy S. Herbst. - Cham :Springer International Publishing :2021. - vi, 264 p. :ill. (some col.), digital ;24 cm. - Current cancer research,2199-2592. - Current cancer research..

Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

ISBN: 9783030740283

Standard No.: 10.1007/978-3-030-74028-3doiSubjects--Topical Terms:

2017391
Lungs
--Cancer

LC Class. No.: RC280.L8

Dewey Class. No.: 616.99424

Lung cancer = new understandings and therapies /
LDR:02328nmm a2200337 a 4500 001 2251525
003 DE-He213
005 20210930163851.0
006 m d
007 cr nn 008maaau
008 220215s2021 sz s 0 eng d
020 $a 9783030740283 $q (electronic bk.)
020 $a 9783030740276 $q (paper)
024 7 $a 10.1007/978-3-030-74028-3 $2 doi
035 $a 978-3-030-74028-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99424 $2 23
090 $a RC280.L8 $b L963 2021
245 0 0 $a Lung cancer $h [electronic resource] : $b new understandings and therapies / $c edited by Anne C. Chiang, Roy S. Herbst.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2021.
300 $a vi, 264 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Current cancer research, $x 2199-2592
505 0 $a Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
520 $a Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
650 0 $a Lungs $x Cancer $x Treatment. $3 2017391
650 1 4 $a Cancer Research. $3 891172
650 2 4 $a Molecular Medicine. $3 890952
650 2 4 $a Oncology. $3 751006
650 0 $a Lungs $x Cancer. $3 815892
700 1 $a Chiang, Anne C. $3 3518608
700 1 $a Herbst, Roy S. $3 3518609
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Current cancer research. $3 1566812
856 4 0 $u https://doi.org/10.1007/978-3-030-74028-3
950 $a Medicine (SpringerNature-11650)